HANSHOW
European retailers are some of the world’s earliest adopters of electronic shelf labels (ESLs) to reduce operations costs as a foundation for retail digitalization. Now at this week’s EuroCIS 2022 trade show, the new IoT platform All-Star is being released and introduced by the digital solutions provider Hanshow (EuroCIS booth - 9 D13), poised to drive Europe’s brick‐and‐mortar retail into a new era of efficiency and profitability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005588/en/
Entering the European market in 2016, Hanshow has been a major driver of this transformation with now nearly 100 million ESLs installed on the continent. This time at EuroCIS 2022, Hanshow is displaying a range of new solutions from AI-powered shelf monitoring to self-checkout trolleys and in-store marketing, constantly shaping smart stores of the future.
Chief among the new technologies presented by Hanshow at EuroCIS is the IoT platform All-Star, focusing on the retail industry and designed specifically to help retailers to expand and upgrade their digitalization. All-Star provides one-stop IoT solutions from IoT device management to digital operations upgrades, empowering retail customers to quickly establish IoT equipment management capabilities and be able to flexibly build business applications and integrate customized business connections to further boost operation efficiency of smart stores and elevate in-store experience of the customers, ranging over key functions of pricing management, inventory management, picking, geolocation, dynamic pricing, promotion boards, interactive marketing, digital payment, passenger flow analysis and automatic monitoring patrol.
The All‐Star platform thus works as an integrated system for the management of a store’s entire digital devices, providing SaaS and private deployment solutions, both of which support unified user authentication and third-party application access integration with an open API based on HTTP. Correspondingly, one of its key product innovations is to solve the new challenges arising with the amount of IoT devices all operating on different networks and communicating on different transmission signals, as one store may require a handful of login systems with operations personnel trained in each. Therefore, each retail solution management platform may now be accessed through All-Star for a holistic integration of all the core business operation processes, significantly simplifying the maintenance of these devices.
In tandem with the All-Star system, Hanshow has also developed an industry-first communications protocol that uses one transmission frequency to communicate with all Hanshow IoT devices, easing the burden on the range of signal frequencies previously needed.
“Hanshow has developed All-Star and the rest of its solutions specifically with global retailers in mind to achieve a more holistic form of digitalization. These new solutions, software, and transmission technologies all combine to help retailers in Europe move into an exciting new era of digitalization,” said Shiguo Hou. “This unlocks great new opportunities. We’re just seeing the beginning of what’s possible.”
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. Hanshow is dedicated to offering its global customers a series of world‐class customized IoT touchpoints and digital store solutions that deliver customer‐centric insights, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Hanshow currently serves over 30,000 stores in more than 50 countries. Learn more: www.hanshow.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005588/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom